Every cell in your body has a built-in oxygen alarm. When oxygen levels drop, a protein called hypoxia-inducible factor, or HIF, accumulates and switches on hundreds of genes that help the cell survive the shortage. This discovery was significant enough to earn the 2019 Nobel Prize in Physiology or Medicine for William Kaelin Jr., Peter Ratcliffe, and Gregg Semenza.1PubMed Central. Discoveries of how cells sense oxygen win the 2019 Nobel Prize in Physiology or medicine The pathway touches everything from how your kidneys produce red blood cells to how tumors resist treatment, and understanding it has already led to new drugs for anemia and cancer.
How Cells Detect Oxygen in the First Place
The oxygen-sensing system is elegantly simple. Under normal oxygen conditions, enzymes called prolyl hydroxylases tag the HIF protein with a small chemical mark, a hydroxyl group, on a specific building block called proline. That tag acts like a “destroy me” signal: it allows a second protein, the von Hippel-Lindau tumor suppressor (pVHL), to grab HIF and send it to the cell’s recycling machinery for rapid breakdown.2PubMed. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing The result is that when oxygen is plentiful, HIF barely exists inside the cell.
When oxygen runs low, the prolyl hydroxylases cannot do their job because they need oxygen as fuel. Without the tag, pVHL has nothing to latch onto, and HIF escapes destruction. It travels to the nucleus, pairs up with a partner called HIF-beta, recruits helper proteins, and lands on short stretches of DNA called hypoxia-responsive elements. From there it cranks up the production of genes the cell needs to cope with the oxygen shortage.3Clinica Chimica Acta. Regulation of gene expression by hypoxia: Integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element The whole system works like a spring-loaded trap: always ready to fire, held back only by the continuous presence of oxygen.
There is also a second layer of control. An enzyme called FIH (factor-inhibiting HIF) uses oxygen to hydroxylate a different part of HIF, blocking its ability to recruit those helper proteins even if some HIF escapes destruction.4PubMed Central. Structure of factor-inhibiting hypoxia-inducible factor 1: An asparaginyl hydroxylase involved in the hypoxic response pathway So the cell effectively has two oxygen-dependent brakes on HIF activity, and both must be released before the pathway fires at full strength.
Two Versions of HIF With Different Timing
Cells actually produce two main forms of the oxygen-sensitive subunit, HIF-1 alpha and HIF-2 alpha, and they do not behave identically. In endothelial cells exposed to low oxygen, HIF-1 peaks at about four hours and then drops sharply by eight hours. HIF-2, by contrast, peaks around eight hours and stays elevated for at least a full day.5PubMed Central. The transition from HIF-1 to HIF-2 during prolonged hypoxia results from reactivation of PHDs and HIF1A mRNA instability This means the cell’s response to a brief oxygen dip looks different from its response to an extended one, because the dominant version of HIF changes over time.
The two forms also control different sets of genes. HIF-1 alpha is the main driver of glycolytic gene expression, the genes that help cells extract energy from sugar without oxygen. HIF-2 alpha does not activate those same genes but instead governs targets involved in blood vessel maturation, red blood cell production, and other long-term adaptations.6PubMed Central. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation In the context of blood vessel growth, HIF-1 alpha handles the early phase, activating endothelial cells and remodeling the tissue scaffold, while HIF-2 alpha sustains the later work of vessel maturation and stabilization during chronic low oxygen.7PubMed Central. The Distinct Role of HIF-1α and HIF-2α in Hypoxia and Angiogenesis Thinking of HIF-1 as the fast responder and HIF-2 as the endurance specialist captures the division of labor reasonably well.
Rewiring Metabolism to Survive Without Oxygen
One of HIF-1’s most immediate effects is to overhaul how the cell generates energy. Normally, cells funnel glucose through a chain of reactions that ends in the mitochondria, where oxygen is consumed to produce large amounts of energy. When oxygen disappears, that last step stalls and dangerous byproducts called reactive oxygen species begin to build up. HIF-1 solves this by flipping a metabolic switch: it activates the gene for pyruvate dehydrogenase kinase 1, or PDK1, which blocks pyruvate from entering the mitochondria. Instead, pyruvate is converted to lactate and shunted out of the cell.8PubMed. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia
At the same time, HIF-1 ramps up glucose transporters and every enzyme in the glycolysis pathway, pulling more sugar into the cell to compensate for the less efficient energy extraction. It also activates a protein called BNIP3, which triggers the selective destruction of mitochondria that are no longer useful and have become a source of toxic byproducts.9PubMed Central. HIF-1: upstream and downstream of cancer metabolism The combined effect is a rapid pivot from oxygen-dependent to oxygen-independent energy production, keeping the cell alive while minimizing internal damage. This same metabolic shift, incidentally, is one reason tumors become so hungry for glucose: cancer cells in oxygen-poor regions of a tumor are running this exact program, often permanently.
Building More Blood Vessels and Red Blood Cells
If cells need oxygen and are not getting enough locally, two broader strategies help: deliver more blood to the area and pack more oxygen into that blood. HIF drives both. One of its primary gene targets is vascular endothelial growth factor, or VEGF, a signaling molecule that stimulates the growth of new blood vessels.10PubMed Central. Vascular endothelial growth factor signaling in hypoxia and inflammation When HIF-1 alpha accumulates in oxygen-starved endothelial cells, it binds directly to the VEGF gene promoter and turns up VEGF production.11PubMed. Critical role of hypoxia sensor–HIF-1α in VEGF gene activation. Implications for angiogenesis and tissue injury healing New capillaries sprout toward the tissue in need, restoring blood flow.
For systemic oxygen delivery, HIF-2 alpha plays the lead role by driving the production of erythropoietin (EPO) in the kidneys and liver. EPO travels through the bloodstream to the bone marrow, where it stimulates the production and maturation of red blood cells. HIF-2 also boosts intestinal iron uptake, ensuring the body has enough raw material to load those red blood cells with hemoglobin.12PubMed Central. Regulation of erythropoiesis by hypoxia-inducible factors This is why people living at high altitude naturally have higher red blood cell counts: their kidneys sense the thinner air, HIF-2 accumulates, EPO rises, and the bone marrow responds.13PubMed. Hypoxia and the HIF system in kidney disease
High-Altitude Adaptation in Tibetans
The HIF pathway has left a visible mark on human evolution. Tibetans, who have lived above 3,000 meters for thousands of years, carry genetic variants in the EPAS1 gene, which encodes HIF-2 alpha. A genome-wide comparison between Tibetan highlanders and closely related lowland Han Chinese revealed strong divergence at EPAS1, with certain alleles found at much higher frequency in Tibetans. Those alleles are associated with lower hemoglobin concentrations, on average about 0.8 g/dL lower in one study, compared to the alternative genotypes.14PubMed Central. Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders
That might seem backward: why would natural selection at high altitude favor lower hemoglobin? The answer is that excessive red blood cell production at altitude makes blood thick and viscous, raising the risk of a dangerous condition called high-altitude polycythemia. Tibetans with the adapted EPAS1 genotype avoid this by blunting the HIF-2 response enough to prevent overproduction of red blood cells. A study of specific EPAS1 variants found that Tibetans with the fully adapted genotype at one site had an average hemoglobin of about 150 g/L, compared with 189 g/L in those carrying the ancestral version.15PubMed Central. Genetic changes in the EPAS1 gene between Tibetan and Han ethnic groups and adaptation to the plateau hypoxic environment Several of these same EPAS1 variants have also been linked to susceptibility to high-altitude polycythemia in the Tibetan population, confirming their real-world clinical significance.16PubMed Central. Association between EPAS1 and ATP6V1E2 polymorphisms and susceptibility to high altitude polycythemia in Chinese Tibetan population
Andean highlanders, who have lived at comparable altitudes for a similar span of time, took a different evolutionary route. Genetic variants at the EGLN1 locus (which encodes one of the prolyl hydroxylase enzymes) that are common in Tibetans are either absent or rare in Andean populations. This suggests that even though both groups adapted to the same physiological challenge, they tweaked different nodes of the same oxygen-sensing pathway.17PubMed Central. Genetic variants at the EGLN1 locus associated with high-altitude adaptation in Tibetans are absent or found at low frequency in highland Andeans Andeans, for instance, tend to have higher hemoglobin levels than Tibetans at equivalent altitudes, reflecting a fundamentally different balance in how their HIF system operates.
When the Pathway Helps Tumors Grow
The same survival toolkit that protects normal cells in low oxygen becomes a liability when hijacked by cancer. Solid tumors often outgrow their blood supply, creating pockets of severe hypoxia deep inside the tumor mass. In those pockets, HIF accumulates and activates its full survival program: metabolic rewiring, new blood vessel growth, and resistance to cell death. But the new vessels formed under hypoxic signaling tend to be leaky and disorganized, which paradoxically perpetuates the low-oxygen environment and creates a vicious cycle.18PubMed Central. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
HIF signaling also helps cancer cells spread. It promotes changes in cell behavior that allow tumor cells to detach from their neighbors, invade surrounding tissue, and seed distant organs. Across a range of tumor types, higher expression of HIF-1 and HIF-2 correlates with increased rates of distant metastasis and worse survival.19PubMed Central. Hypoxic control of metastasis Hypoxia also makes tumors harder to treat: cells in low-oxygen zones tend to enter a dormant state that renders them less sensitive to chemotherapy and radiation, both of which work best on actively dividing cells.
VHL Loss and Clear Cell Kidney Cancer
Nowhere is the link between the hypoxia pathway and cancer more direct than in clear cell renal cell carcinoma, the most common type of kidney cancer. The majority of these tumors carry mutations that inactivate both copies of the VHL gene, the same gene whose protein normally tags HIF for destruction. Without functional pVHL, HIF-1 alpha and HIF-2 alpha accumulate constitutively, regardless of how much oxygen is available.20Frontiers in Oncology. Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel–Lindau-Deficient Renal Cancer The cell behaves as though it is permanently suffocating, turning on VEGF, glucose transporters, and growth signals nonstop. This is why clear cell kidney tumors are typically rich in blood vessels and heavily dependent on glycolysis.21PubMed. VHL and HIF signalling in renal cell carcinogenesis
The dependence on HIF-2 alpha in these tumors created an obvious drug target. Belzutifan, the first FDA-approved drug to directly inhibit HIF-2 alpha, was approved in 2021 for patients with von Hippel-Lindau disease, a hereditary condition in which VHL is mutated throughout the body, causing tumors and cysts in multiple organs. In the pivotal trial, about half of patients with kidney tumors had objective tumor shrinkage, and responses were also seen in pancreatic lesions and central nervous system tumors associated with the disease.22PubMed Central. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease By 2023, belzutifan also received approval for advanced sporadic clear cell kidney cancer that had progressed through other treatments, and trials are exploring it in earlier treatment lines and in combination with other drugs.23PubMed Central. Belzutifan for the treatment of renal cell carcinoma
Drugs That Activate the Pathway on Purpose
While oncologists are trying to block HIF in cancer, nephrologists have taken the opposite approach: activating HIF to treat anemia. People with chronic kidney disease often cannot make enough EPO because their damaged kidneys no longer sense oxygen drops properly. For decades, the standard treatment has been injections of synthetic EPO, which works but requires refrigeration, needles, and careful dose titration to avoid pushing hemoglobin too high.
A newer class of drugs called HIF-prolyl hydroxylase inhibitors (HIF-PHIs) takes a more upstream approach. These oral pills block the prolyl hydroxylase enzymes that mark HIF for destruction. With those enzymes inhibited, HIF accumulates even at normal oxygen levels, stimulating the kidneys to produce their own EPO and improving iron absorption from the gut.24PubMed Central. HIF-prolyl hydroxylase inhibitors in renal anemia: current clinical experience The result is a more physiological rise in red blood cells compared to the sometimes abrupt spike from EPO injections.25PubMed Central. Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia Several HIF-PHIs are already approved in various countries, and their convenience as oral medications is a genuine shift for patients who previously needed regular clinic visits for EPO injections.
Ischemia and the Heart
During a heart attack, blood flow to part of the heart muscle drops abruptly, creating severe local hypoxia. HIF accumulates rapidly in the affected tissue and activates genes for glycolysis, cell survival, and protection against oxidative damage. In principle, this response should help the heart muscle survive until blood flow is restored. And there is evidence from experimental models that pre-activating HIF before an ischemic event does confer protection, a concept loosely related to the well-known phenomenon of ischemic preconditioning.26Cell Death & Differentiation. Role of hypoxia-inducible factor in cell survival during myocardial ischemia–reperfusion
The catch is timing. HIF activation helps most when it precedes the ischemic insult, allowing protective genes to ramp up before disaster strikes. Once ischemia is already severe and sustained, the protective window narrows. And when blood flow suddenly returns (reperfusion), the flood of oxygen generates a burst of reactive oxygen species that can cause additional damage. The genes HIF activates, including those for oxygen-independent energy generation and angiogenesis, can limit this reperfusion injury to some extent, making the HIF pathway a target of interest for cardioprotective strategies.27PubMed Central. The role of HIFs in ischemia-reperfusion injury
Hypoxia and the Lung Vasculature
In most tissues, hypoxia causes blood vessels to relax and widen, bringing in more blood. The lungs do the opposite. When part of the lung is poorly ventilated and oxygen levels drop locally, the blood vessels in that region constrict, diverting blood toward better-ventilated areas. This reflex, called hypoxic pulmonary vasoconstriction, is useful in small doses but can become pathological. Chronic exposure to low oxygen, whether from lung disease, living at extreme altitude, or sleep apnea, can lead to sustained constriction and remodeling of pulmonary blood vessels. HIF-1 alpha in smooth muscle cells is a contributor to this remodeling, promoting the thickening of vessel walls that characterizes pulmonary hypertension.28PubMed Central. Differential regulation of pulmonary vascular cell growth by hypoxia-inducible transcription factor-1α and hypoxia-inducible transcription factor-2α Both HIF-1 alpha and HIF-2 alpha appear to contribute, but HIF-1 alpha in vascular smooth muscle has been specifically implicated in driving the structural changes of chronic hypoxic pulmonary hypertension.29American Journal of Respiratory and Critical Care Medicine. Regulation of Hypoxia-induced Pulmonary Hypertension by Vascular Smooth Muscle Hypoxia-Inducible Factor-1α
Why Intermittent Hypoxia Is Especially Damaging
Not all oxygen deprivation is equal. People with obstructive sleep apnea experience something distinct from the steady low oxygen of high altitude: they cycle between normal oxygen during waking hours and repeated drops during sleep, hundreds of times per night. This pattern of intermittent hypoxia appears to be uniquely harmful. In a study of human heart muscle cells, intermittent hypoxia produced an earlier and more intense inflammatory response than either constant mild hypoxia or normal oxygen. Cells released higher levels of inflammatory signaling molecules and VEGF, and showed greater injury as measured by cell loss and enzyme leakage.30PubMed. Intermittent Hypoxia Causes Inflammation and Injury to Human Adult Cardiac Myocytes The gene expression changes pointed toward oxidative stress pathways rather than the clean metabolic switch that sustained hypoxia produces. This helps explain why sleep apnea carries cardiovascular risks out of proportion to the actual oxygen levels involved: it is the oscillation, not just the depth, that does the damage.
HIF Activation Beyond Low Oxygen
One of the surprises of hypoxia research has been discovering that HIF does not respond only to oxygen levels. Growth factors, reactive oxygen species, nitric oxide, certain metal ions, and even mechanical stress can all stabilize HIF-1 alpha and activate the pathway in cells that have plenty of oxygen.31PubMed Central. Oxygen-dependent and -independent regulation of HIF-1alpha This is relevant in inflamed tissues, where immune cells release signals that can push HIF levels up through oxygen-independent routes. It means that the “hypoxia pathway” is a bit of a misnomer: HIF is really a stress integrator that responds to oxygen shortage as its primary trigger but can be engaged by other forms of cellular distress.
In inflamed tissue, low oxygen and immune activation converge on the same pathway. Immune cells that migrate from oxygen-rich blood into damaged or infected tissue encounter genuinely hypoxic conditions. HIF helps these cells adapt: it adjusts their metabolism, supports their ability to kill bacteria, and regulates the production of inflammatory signaling molecules.32PubMed Central. Hypoxia, Metabolism and Immune Cell Function Rather than simply being a byproduct of inflammation, hypoxia actively shapes the immune response, creating feedback loops where immune activity worsens oxygen depletion and oxygen depletion amplifies immune signaling.33JCI Insight. Hypoxia-dependent regulation of inflammatory pathways in immune cells
How Diving Mammals Handle Repeated Ischemia
If intermittent hypoxia is so damaging in humans, how do deep-diving marine mammals survive? Species like elephant seals and sperm whales routinely experience dramatic drops in blood flow to their peripheral tissues during dives, effectively undergoing repeated bouts of ischemia and reperfusion that would cause significant tissue injury in terrestrial mammals. Yet they show no apparent harmful effects from these cycles.34PubMed Central. Natural Tolerance to Ischemia and Hypoxemia in Diving Mammals: A Review The mechanisms behind this tolerance are still being studied, but they likely include enhanced antioxidant defenses, tissue-level adaptations to buffer oxygen swings, and potentially modified HIF signaling that differs from the terrestrial mammalian blueprint. For researchers studying ischemia-reperfusion injury in human hearts and brains, these animals represent a natural experiment in how evolution can solve a problem that remains one of the biggest killers in modern medicine.